Ginkgo, Eagle + Acacia, Gilead, Taysha/Orchard/Silverback

Big compensation, mild mergers, a Kite in an updraft, and tightening the biotech belt

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Ginkgo
Eagle + Acacia
Gilead
Taysha/Orchard/Silverback

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

2seventy Bio, Ascendis, Apellis, Argenx

$2 billion in capital raises mostly by companies that start with the letter A.
 
Find out more at
https://LifeScienceTodayPodcast.com

Story References
2seventy Bio
Ascendis
Apellis
Argenx

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Alexion + Chugai, Biogen, Viatris, AbbVie

Case closed on patents, Alzheimer’s data, generic approvals, and expanded approvals.  

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Alexion + Chugai
Biogen
Viatris
AbbVie

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Tech-clusion, Gilead, AstraZeneca + Merck + Myriad, DNAnexus

Technology for inclusion, layoffs, oncology approvals, and $200M for a tech platform.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Gilead
AstraZeneca + Merck + Myriad
DNAnexus


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

CRISPR Pt 2, Sanofi + Adagene, AbbVie + Syndesi, Atlas

Who owns CRISPR, a collaboration, the classics, and more money for biotech.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Sanofi + Adagene
AbbVie + Syndesi
Atlas


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Intellia + Regeneron, Purdue, Amicus

CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’t

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Intellia
Purdue Pharma
Amicus SPAC

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.